Combretastatin A4 phosphate;La combrétastatine A4 phosphate

Bulletin du Cancer

Volumn 88, Issue 3, 2001, Pages 235-239

  Verdier Pinard, P ^a   Lansiaux, A ^a   Bailly, C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

CYTOTOXICITY; DRUG MECHANISM; MICROTUBULE ASSEMBLY; MITOSIS INDEX; MULTIDRUG RESISTANCE; MURINE LEUKEMIA; NONHUMAN; PHENOTYPE; PROTEIN POLYMERIZATION; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIBENZYLS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; STILBENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0035058046     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
2. Isolation and structure of combretastatin
3. Synthesis of natural (-) combretastatin
4. Cell growth inhibitory dihydrophenanthrene and phenanthene constituents of the African tree Combretum caffrum
5. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum
6. Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2
7. Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from Combretum caffrum
8. Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin
9. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structure-activity study
10. Quantitative structure-activity relationship analysis of combretastatins: A class of novel antimitotic agents
11. Novel combretastatin analogues effective against murine solid tumors: Design and structure-activity relationships
12. Antineoplastic agents. 379. Synthesis of phenstatin phosphate
13. The interaction with tubulin of a series of stilbenes based on combretastatin A-4
14. Differential cytotoxicity of combretastatins A-1 and A-4 in two daunorubicin-resistant P388 cell lines
15. Colchicine in the experimental chemotherapy of cancer
16. Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A-4
17. Antimitotic natural products and their interactions with tubulin
18. Mechanisms of action and of resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death
19. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents
20. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy
21. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding Of colchicine to tubulin
22. Synthesis and biological evaluation of aryl azide derivatives of combrerastatin A-4 as molecular probes for tubulin
23. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
24. Induction of apoprosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
25. Activity of combretastatin A-4 against B cell leukemia and lymphoma
26. Science, medicine, and the future. Antivascular therapy: A new approach to cancer treatment
27. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
28. Quantitative analysis of endothelial cell shape change after treatment with combretastatin A-4 phosphate
29. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs
30. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug
31. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A-4 phosphate
32. Magnetic resonance imaging and spectroscopy of combretastatin A-4 prodrug-induced disruption of tumour perfusion and energetic status
33. Combretastatin A-4 disodium phosphate: A novel tubulin binding agent with potent activity in murine tumours
34. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors
35. Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide
36. Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4
37. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
38. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma
39. An angiogenesis inhibitor: TNP470
40. Combretastatin A-4 phosphate depletes tumor energy and enhances the effect of mitomycin C but not radiation in murine mammary carcinoma
41. Effects of the vascular targeting agent combretastatin A-4 disodium phosphate (CA-4DP) in Kaposi's sarcoma
42. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma
43. Combretastatin A-4 phosphate (CA-4-P) selectively targets vasculature in animal and human tumors
44. Phase I pharmacokinetic study of single dose intravenous (IV) combretastatin A-4 prodrug (CA-4-P) in patients with advanced cancers
45. Phase I/pharmacokinetic trial of the endothelial toxin combretastatin A-4P (CA-4-P) administered as an IV bolus on a daily x 5 schedule every 21 days
46. ZD6126: A new agent causing selective damage of tumor vasculature
47. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol